News Detail
Baltimore, 2 March 2018: Researchers at Johns Hopkins University School of Medicine have developed a new class of bifunctional antibody-based immunotherapy that targets immune checkpoints, but simultaneously disables the production of immunosuppressive regulatory T cells (Tregs).......
View Details
Source : Genetic Engineering & Biotechnology News
Related News
- Immune Cells Vital to Success of Vaccines Against Coronavirus: Study (24-09-2023)
- New target to beat cancer drug resistance (21-09-2023)
- New implantable device carries insulin-producing islet cells to control diabetes (20-09-2023)
- IIT Madras Researchers Developing A Portable, Turnkey Device To Detect Heavy Metals In Soil & Water (20-09-2023)
- Understanding Medicinal Drug Delivery Using Dry Powder Inhalers (DPIs) (20-09-2023)
- Molnupiravir: Concerns raised about possibility of creating new, treatment-resistant versions of the virus (19-09-2023)
- Various PFAS associated with breast, ovary, skin and uterus cancers in women (19-09-2023)
- IIT Jodhpur researchers develop antimicrobial peptide from snake venom (18-09-2023)
- Metformin, a common diabetes drug, can prevent muscle atrophy and fibrosis (17-09-2023)
- Layered Black Phosphorus Nanoflakes can kill antibiotic resistant superbugs (16-09-2023)